Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference
Anixa Biosciences (NASDAQ: ANIX) has announced its participation in the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference, scheduled for September 25-27, 2024. Dr. Pamela Garzone, Anixa's Chief Development Officer, will present on the company's innovative CAR-T therapy for ovarian cancer on September 25 at 3:00 PM ET. The presentation, titled "Autologous T Cells Engineered to Target Follicle Stimulating Hormone (FSH) Receptor in Recurrent Ovarian Cancer, A Phase 1 Trial," will focus on the clinical development of this novel treatment approach. This conference, organized by OCRA, the world's leading organization in the fight against ovarian cancer, provides a platform for Anixa to showcase its advancements in cancer treatment and prevention.
Anixa Biosciences (NASDAQ: ANIX) ha annunciato la sua partecipazione alla Conferenza Internazionale sulla Cancro Ginecologico dell'Ovario, che si terrà dal 25 al 27 settembre 2024. Il Dott. Pamela Garzone, Direttore dello Sviluppo di Anixa, presenterà la terapia CAR-T innovativa per il cancro ovarico il 25 settembre alle 15:00 ET. La presentazione, intitolata "Cellule T Autologhe Ingegnerizzate per Mirare al Recettore dell'Ormone Follicolare Stimolante (FSH) nel Cancro Ovarico Ricorrente, Uno Studio di Fase 1", si concentrerà sullo sviluppo clinico di questo approccio terapeutico innovativo. Questa conferenza, organizzata da OCRA, l'organizzazione leader mondiale nella lotta contro il cancro ovarico, offre ad Anixa una piattaforma per mostrare i suoi progressi nel trattamento e nella prevenzione del cancro.
Anixa Biosciences (NASDAQ: ANIX) ha anunciado su participación en la Conferencia Internacional sobre Cáncer Ginecológico de la Alianza para la Investigación del Cáncer de Ovario, programada del 25 al 27 de septiembre de 2024. La Dra. Pamela Garzone, Directora de Desarrollo de Anixa, presentará la innovadora terapia CAR-T para el cáncer de ovario el 25 de septiembre a las 3:00 PM ET. La presentación, titulada "Células T Autólogas Ingenierizadas para Objetivar el Receptor de la Hormona Estimulante del Folículo (FSH) en el Cáncer de Ovario Recurrente, Un Ensayo de Fase 1", se centrará en el desarrollo clínico de este nuevo enfoque de tratamiento. Esta conferencia, organizada por OCRA, la principal organización mundial en la lucha contra el cáncer de ovario, proporciona a Anixa una plataforma para mostrar sus avances en el tratamiento y la prevención del cáncer.
Anixa Biosciences (NASDAQ: ANIX)는 난소암 연구 연합의 국제 부인과 암 회의에 참여할 것이라고 발표했습니다. 이 회의는 2024년 9월 25일부터 27일까지 예정되어 있습니다. Anixa의 개발 책임자인 드. 파멜라 가존이 9월 25일 오후 3시 ET에 난소암에 대한 혁신적인 CAR-T 치료법에 대해 발표할 예정입니다. 발표 제목은 "재발성 난소암에서 난포 자극 호르몬(FSH) 수용체를 목표로 하는 자가 T 세포 엔지니어링, 1상 시험"으로, 이 새로운 치료 접근법의 임상 개발에 중점을 둘 것입니다. OCRA가 주최하는 이 회의는 난소암 퇴치에서 세계 최고의 조직으로, Anixa가 암 치료 및 예방을 위한 진전을 전시할 수 있는 플랫폼을 제공합니다.
Anixa Biosciences (NASDAQ: ANIX) a annoncé sa participation à la Conférence Internationale sur le Cancer Gynécologique de l'Alliance pour la Recherche sur le Cancer de l'Ovaire, prévue du 25 au 27 septembre 2024. Le Dr Pamela Garzone, Directrice du Développement d'Anixa, présentera la thérapie CAR-T innovante pour le cancer de l'ovaire le 25 septembre à 15h00 ET. La présentation, intitulée "Cellules T Autologues Ingénierées visant le Récepteur de l'Hormone Folliculo-Stimulante (FSH) dans le Cancer Ovarien Récidivant, Un Essai de Phase 1", se concentrera sur le développement clinique de cette approche thérapeutique novatrice. Cette conférence, organisée par l'OCRA, la principale organisation mondiale dans la lutte contre le cancer de l'ovaire, offre à Anixa une plateforme pour présenter ses avancées dans le traitement et la prévention du cancer.
Anixa Biosciences (NASDAQ: ANIX) hat seine Teilnahme an der Internationalen gynäkologischen Krebs-Konferenz der Ovarian Cancer Research Alliance angekündigt, die vom 25. bis 27. September 2024 stattfinden wird. Dr. Pamela Garzone, Chief Development Officer von Anixa, wird am 25. September um 15:00 Uhr ET über die innovative CAR-T-Therapie für Eierstockkrebs referieren. Die Präsentation mit dem Titel "Autologe T-Zellen, die auf den Follikel-stimulierenden Hormon(FSH)-Rezeptor bei rezidivierendem Eierstockkrebs abzielen, eine Phase-1-Studie", wird sich auf die klinische Entwicklung dieses neuartigen Behandlungsansatzes konzentrieren. Diese Konferenz, organisiert von OCRA, der weltweit führenden Organisation im Kampf gegen Eierstockkrebs, bietet Anixa eine Plattform, um seine Fortschritte in der Krebsbehandlung und -prävention zu demonstrieren.
- Anixa Biosciences is presenting its novel CAR-T therapy for ovarian cancer at a major international conference
- The company's research is focused on a specific target: Follicle Stimulating Hormone (FSH) Receptor in recurrent ovarian cancer
- Participation in the conference may increase visibility and credibility for Anixa's ovarian cancer treatment approach
- None.
The presentation, entitled "Autologous T Cells Engineered to Target Follicle Stimulating Hormone (FSH) Receptor in Recurrent Ovarian Cancer, A Phase 1 Trial," will be presented by Dr. Pamela Garzone, Anixa's Chief Development Officer, and will discuss the clinical development of Anixa's novel chimeric antigen receptor T cell (CAR-T) therapy for ovarian cancer. The presentation will take place at 3:00PM ET on September 25.
The International Gynecologic Cancer Conference is organized by OCRA. OCRA is the leading organization in the world fighting ovarian cancer from all fronts while supporting women and their families.
More information about the event may be found at: International Gynecologic Cancer Conference - Ovarian Cancer Research Alliance (ocrahope.org).
About Anixa's CAR-T Approach (Follicle Stimulating Hormone Receptor-Mediated CAR-T technology)
Anixa's chimeric antigen receptor-T cell (CAR-T) technology approach is an autologous cell therapy comprised of engineered T cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone (chimeric endocrine) receptor, and the target-binding domain is derived from its natural ligand, this technology is known as CER-T (chimeric endocrine receptor-T cell) therapy, a new type of CAR-T. Anixa's FSHR-mediated CAR-T technology was developed by Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine. Anixa holds an exclusive world-wide license to the technology from The Wistar Institute.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-on-its-ovarian-cancer-car-t-therapy-at-the-ovarian-cancer-research-alliances-international-gynecologic-cancer-conference-302251762.html
SOURCE Anixa Biosciences, Inc.
FAQ
What is Anixa Biosciences presenting at the OCRA International Gynecologic Cancer Conference?
When and where is Anixa Biosciences (ANIX) presenting at the OCRA conference?
Who is presenting Anixa Biosciences' (ANIX) research at the OCRA conference?
What type of cancer treatment is Anixa Biosciences (ANIX) developing?
